PROK Insider Trading

Insider Ownership Percentage: 41.49%
Insider Buying (Last 12 Months): $74,735,337.82
Insider Selling (Last 12 Months): $345,310.61

ProKidney Insider Trading History Chart

This chart shows the insider buying and selling history at ProKidney by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$50M$0$50MTotal Insider BuyingTotal Insider Selling

ProKidney Share Price & Price History

Current Price: $0.73
Price Change: Price Increase of +0.1178 (19.20%)
As of 04/11/2025 05:00 PM ET

This chart shows the closing price history over time for PROK up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$0.73Closing price on 04/11/25:

SEC Filings (Institutional Ownership Changes) for ProKidney (NASDAQ:PROK)

51.59% of ProKidney stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at PROK by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$202kbought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$10M-$5M$0$5M$10MTotal InflowsTotal Outflows
ProKidney logo
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Read More on ProKidney

Today's Range

Now: $0.73
Low: $0.60
High: $0.73

50 Day Range

MA: $1.10
Low: $0.51
High: $1.67

52 Week Range

Now: $0.73
Low: $0.46
High: $4.44

Volume

606,347 shs

Average Volume

690,080 shs

Market Capitalization

$214.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52

Who are the company insiders with the largest holdings of ProKidney?

ProKidney's top insider shareholders include:
  1. Control Empresarial De Capital (Insider)
  2. Pablo G Legorreta (Director)
  3. Chamath Palihapitiya (Major Shareholder)
  4. Darin J Weber (SVP)
  5. Darin J Weber (Insider)
Learn More about top insider investors at ProKidney.

Who are the major institutional investors of ProKidney?

ProKidney's top institutional shareholders include:
  1. Hennion & Walsh Asset Management Inc. — 0.29%
Learn More about top institutional investors of ProKidney stock.

Which major investors are buying ProKidney stock?

During the previous quarter, PROK stock was acquired by institutional investors including:
  1. Hennion & Walsh Asset Management Inc.
In the previous year, these company insiders have bought ProKidney stock:
  1. Control Empresarial De Capital (Insider)
  2. Pablo G Legorreta (Director)
Learn More investors buying ProKidney stock.